These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 31985581)

  • 1. Misdiagnosis of High-grade Serous Ovarian Cancer With BRCA Mutation as Endometriotic Cyst Due to Its Unique Gross Morphology: A Case Report and Literature Review.
    Ma Q; Yuan Y; Wang Y; Shao C; Feng W
    Int J Gynecol Pathol; 2021 Mar; 40(2):165-168. PubMed ID: 31985581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer.
    Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
    J Ovarian Res; 2019 May; 12(1):40. PubMed ID: 31064392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical significance and distribution of BRCA genes mutation in sporadic high grade serous ovarian cancer].
    Liu WL; Wang ZZ; Zhao JZ; Hou YY; Wu XX; Li W; Dong B; Tong TT; Guo YJ
    Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):26-31. PubMed ID: 28190312
    [No Abstract]   [Full Text] [Related]  

  • 5. BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study.
    Marchetti C; De Leo R; Musella A; D'Indinosante M; Capoluongo E; Minucci A; Benedetti Panici P; Scambia G; Fagotti A
    Ann Surg Oncol; 2018 Nov; 25(12):3701-3708. PubMed ID: 30128899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The "Far Left" of the Morphologic Spectrum of Ovarian High-grade Serous Carcinoma: Case Report of a Purely Noninvasive High-grade Serous Carcinoma Mimicking an Ovarian Serous Borderline Tumor.
    Katsakhyan L; Baraban EG; Dumoff KL; Burger RA; Parikh R; Cooper K
    Int J Gynecol Pathol; 2021 Mar; 40(2):175-179. PubMed ID: 32168063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of Tissue BRCA Gene Mutation in Ovarian, Fallopian Tube, and Primary Peritoneal Cancers: A Multi-Institutional Study.
    Lertkhachonsuk AA; Suprasert P; Manchana T; Kittisiam T; Kantathavorn N; Chansoon T; Khunamornpong S; Pohthipornthawat N; Tangjitgamol S; Luasiripanthu T; Teerapakpinyo C; Shuangshot S; Iemwimangsa N; Chantratita W
    Asian Pac J Cancer Prev; 2020 Aug; 21(8):2381-2388. PubMed ID: 32856869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival and Chemosensitivity in Advanced High Grade Serous Epithelial Ovarian Cancer Patients with and without a BRCA Germline Mutation: More Evidence for Shifting the Paradigm towards Complete Surgical Cytoreduction.
    De Jong D; Otify M; Chen I; Jackson D; Jayasinghe K; Nugent D; Thangavelu A; Theophilou G; Laios A
    Medicina (Kaunas); 2022 Nov; 58(11):. PubMed ID: 36363568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
    Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of endometriotic cysts and ovarian cancer in association with endometriotic cysts.
    Yamamoto Y; Wakikawa A; Ueno A; Nagai R; Matsumoto M; Komatsu J; Kinoshita H; Minami S; Hayashi K
    Cancer Treat Res Commun; 2018; 14():26-29. PubMed ID: 30104005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.
    Garg K; Levine DA; Olvera N; Dao F; Bisogna M; Secord AA; Berchuck A; Cerami E; Schultz N; Soslow RA
    Am J Surg Pathol; 2013 Jan; 37(1):138-46. PubMed ID: 23232854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The BRCA1 c.788G > T (NM_007294.4) variant in a high grade serous ovarian cancer (HGSOC) patient: foods for thought.
    De Paolis E; Pietragalla A; De Bonis M; Fagotti A; Urbani A; Scambia G; Minucci A
    Mol Biol Rep; 2021 Mar; 48(3):2985-2992. PubMed ID: 33656647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of serous tubal intraepithelial carcinoma (STIC) in patients with high grade serous ovarian cancer.
    Byun JM; Cho HJ; Lee DS; Yoon HK; Kim YN; Im DH; Kim DH; Lee KB; Sung MS; Jeong DH
    Taiwan J Obstet Gynecol; 2023 Jan; 62(1):107-111. PubMed ID: 36720520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The risk of malignancy with an apparently simple adnexal cyst on ultrasound.
    Obwegeser R; Deutinger J; Bernascheck G
    Arch Gynecol Obstet; 1993; 253(3):117-20. PubMed ID: 8250597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas.
    Dowson CB; Stewart C; O'Sullivan S; Pachter N; Schofield L; Cohen PA
    Int J Gynecol Cancer; 2020 Jan; 30(1):94-99. PubMed ID: 31699802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between CT-texture-derived tumor heterogeneity, outcomes, and BRCA mutation status in patients with high-grade serous ovarian cancer.
    Meier A; Veeraraghavan H; Nougaret S; Lakhman Y; Sosa R; Soslow RA; Sutton EJ; Hricak H; Sala E; Vargas HA
    Abdom Radiol (NY); 2019 Jun; 44(6):2040-2047. PubMed ID: 30474722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma.
    Wallbillich JJ; Morris RT; Ali-Fehmi R
    Gynecol Oncol; 2020 Nov; 159(2):381-386. PubMed ID: 32900500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
    Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S
    BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
    Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J
    Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal changes in magnetic resonance imaging of malignant and borderline tumors associated with ovarian endometriotic cyst comparing with endometriotic cysts without arising malignancy.
    Nishio N; Kido A; Kataoka M; Kuwahara R; Nakao K; Kurata Y; Matsumura N; Mandai M; Togashi K
    Eur J Radiol; 2018 Aug; 105():175-181. PubMed ID: 30017276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.